

## Overview table uncertainty 1 asthma deaths

These Cochrane Airways reviews have been identified by the Cochrane Airways group as being relevant to the uncertainties around asthma deaths.

Intervention	Review information					Number search records (date)	Number new studies (N participants)	Action
	ID	Search date	Number of studies	Number of participants	Outcomes (listed in SOF table)			
Drugs								
Increased versus stable doses of inhaled corticosteroids for exacerbations of chronic asthma in adults and children	DOS E-AST	24 March 2016	8	1669	Treatment failure needs for systemic steroids, unscheduled physician visits, unscheduled ED visit of hospitalisation, duration of exacerbations, SAEs	Not searched	1 (1922)	Update needed
Inhaled steroids with and without regular salmeterol for asthma: serious adverse events	LAB3-AST	10 October 2018	49	27,951	Mortality (all cause), non-fatal SAEs (all cause), mortality (asthma related), non-fatal SAE (asthma related)			Up-to-date
Combination formoterol and budesonide as maintenance and reliever therapy versus current best practice (including inhaled steroid maintenance), for chronic asthma in adults and children	CFI1-AST	14 February 2013	14	13,376	Exacerbations requiring hospitalisation, exacerbations requiring OCS, fatal SAEs, SAEs (non-fatal), withdrawal due to AEs			
Regular treatment with salmeterol for chronic	LAB1-AST	17 August 2011	32	62,815	Mortality (all cause), non-fatal SAEs (all cause), mortality	-	-	No update planned: Due to safety concerns, inhaled

asthma: serious adverse events					(asthma related), non-fatal SAE (Asthma related)			LABA are now always given with ICS in asthma.
Regular treatment with formoterol versus regular treatment with salmeterol for chronic asthma: serious adverse events	LAB5 -AST	05 January 2012	4	272	Mortality (all cause), non-fatal SAEs (all cause), mortality (asthma related), non-fatal SAE (asthma related)	-	-	No update planned: Due to safety concerns, inhaled LABA are now always given with ICS in asthma.
Inhaled steroids with and without regular formoterol for asthma: serious adverse events	LAB4 -AST	18 February 2019	42	39,786	Mortality (all cause), non-fatal SAEs (all cause), mortality (asthma related), non-fatal SAE (Asthma related)	-	-	Up-to-date
Regular treatment with formoterol for chronic asthma: serious adverse events	LAB2 -AST	05 January 2012	23	8032	Mortality (all cause), non-fatal SAEs (all cause), mortality (asthma related), non-fatal SAE (asthma related)	-	-	No update planned: Due to safety concerns, inhaled LABA are now always given with ICS in asthma.
Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma: serious adverse events	LAB6 -AST	17 August 2011	10	6769	Mortality (all cause), non-fatal SAEs (all cause), mortality (asthma related), non-fatal SAE (asthma related)	-	-	Currently being updated
<b>Non-drug</b>								
Personalised asthma action plans for adults with asthma	PAAP -AST	14 September 2016	15	2602	Exacerbations requiring ED visit or hospitalisation, asthma control change from baseline in ACQ, SAEs, AQLQ, exacerbation requiring OCS, change from baseline FEV1, days lost from work or study.	Searched Cochrane Airways Register of Trials 24 April 2020	1 (N=320)	No update planned as 1 small study unlikely to change conclusions. Assess for updating in 3 years.

Remote versus face-to-face check-ups for asthma	TELE 1-AST	24 November 2015	6	2100	Exacerbations requiring OCS, exacerbations requiring hospitalisation, ACQ, SAEs, AQLQ, unscheduled healthcare visits, trough FEV1.			Run update search
Pulse oximeters to self-monitor oxygen saturation levels as part of a personalised asthma action plan for people with asthma	PUL-AST	04 March 2015	0	0	-	0 (24 July 2018)		

Abbreviations:

ACQ: asthma control questionnaire; AQLQ: asthma quality of life questionnaire; ED: emergency department; FEV1: forced expiratory volume in one second; FVC: forced vital capacity; ICS: inhaled corticosteroid; LABA: long-acting beta<sub>2</sub>-agonist; SAEs: serious adverse events